Palliative Care Team, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
J Pain Symptom Manage. 2018 Jun;55(6):1557-1563. doi: 10.1016/j.jpainsymman.2018.03.016. Epub 2018 Mar 23.
Few patient-reported outcomes are available to measure the symptoms associated with malignant-related ascites in patient care and clinical research. Although the Edmonton Symptom Assessment System: Ascites Modification (ESAS:AM) is a brief tool to measure symptoms associated with malignant-related ascites, it remains to be fully validated.
The objective of the study was to validate the ESAS:AM in Japanese cancer patients.
We assessed the internal consistency, test-retest reliability, concurrent validity, and construct validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS:AM, M.D. Anderson Symptom Inventory, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module.
Cronbach's alpha coefficient of the ESAS:AM was 0.89. The intraclass correlation coefficient on test-retest examination of its total score was 0.93 (P < 0.001). Pearson correlation coefficients of the total score of the ESAS:AM with the total score of the M.D. Anderson Symptom Inventory and abdominal pain/ascites subscales of the EORTC Core Quality of Life Questionnaire, 26-item pancreatic cancer module ranged from 0.44 to 0.81 (P < 0.001) and those with global health status/quality of life and functional subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 ranged from -0.40 to -0.61 (P < 0.001). The total scores of the ESAS:AM were significantly higher in 20 patients with symptomatic ascites (34 [SD, 26]) than 267 patients without symptomatic ascites (23 [SD, 19]) (P = 0.018).
The ESAS:AM is a reliable and valid tool for measuring symptoms associated with malignant-related ascites and can be used in daily patient care and future epidemiological studies and clinical trials.
在患者护理和临床研究中，很少有患者报告的结果可用于测量与恶性相关腹水相关的症状。尽管埃德蒙顿症状评估系统：腹水改良版（ESAS：AM）是一种用于测量与恶性相关腹水相关症状的简短工具，但仍需要充分验证。
本研究旨在验证 ESAS：AM 在日本癌症患者中的有效性。
我们评估了 292 名日本成年癌症患者的内部一致性、重测信度、同时效度和结构效度。他们完成了 ESAS：AM、安德森症状评估量表、欧洲癌症研究与治疗组织核心 30 生活质量问卷、EORTC 核心生活质量问卷腹部疼痛/腹水子量表和胰腺 26 项癌症模块的日文版。
ESAS：AM 的克朗巴赫 α 系数为 0.89。其总分的重测信度的组内相关系数为 0.93（P<0.001）。ESAS：AM 总分与安德森症状评估量表总分和 EORTC 核心生活质量问卷腹部疼痛/腹水子量表、胰腺 26 项癌症模块的总得分的皮尔逊相关系数范围为 0.44 至 0.81（P<0.001），与全球健康状况/生活质量和欧洲癌症研究与治疗组织核心 30 生活质量问卷功能子量表的相关系数范围为-0.40 至-0.61（P<0.001）。有症状腹水的 20 名患者（34 [SD，26]）的 ESAS：AM 总分明显高于无有症状腹水的 267 名患者（23 [SD，19]）（P=0.018）。
ESAS：AM 是一种可靠有效的工具，可用于测量与恶性相关腹水相关的症状，可用于日常患者护理以及未来的流行病学研究和临床试验。
